[1] HURWITZ H, FEHRENBACHER L, NOVOTNY W. Bevacizumab plus irinotecan,fluorouracil,and leucovorin for metastatic colorectal cancer. 2004(23). doi:10.1056/NEJMoa032691
[2] VENOOK A. Critical evaluation of current treatments in metastatic colorectal cancer, 2005(4)
[3] KABBINAVAR F F, SCHULZ J, McCLEOD M. Addition of bevacizumab to bolus fiuorouracil and leucovorin in first-line metastatic colorectal cancer:results of a randomized phase Ⅱ trial. 2005(16). doi:10.1200/JCO.2005.05.112
[4] SANDLER A, GRAY R, PERRY M C. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. 2006(24). doi:10.1056/NEJMoa061884
[5] SANDLER A, HERBST R. Combining targeted agents:blocking the epidermal growth factor and vascular endothelial growth factor pathways. 2006(1). doi:10.1158/1078-0432.CCR-06-0796
[6] SLEDGE G W, RUGO H S, BURSTEIN H J. The role of angiogenesis inhibition in the treatment of breast cancer, 2006(10)
[7] OZOLS R F. Systemic therapy for ovarian cancer:current status and new treatments. 2006(z6). doi:10.1053/j.seminoncol.2006.03.011
[8] MOTZER R J, BUKOWSKI R M. Targeted therapy for metastatic renal cell carcinoma. 2006(35). doi:10.1200/JCO.2006.08.5415
[9] CAMP E R, YANG A, LIU W. Roles of nitric oxide synthase inhibition and vascular endothelial growth factor receptor-2 inhibition on vascular morphology and function in an in vivo model of pancreatic cancer. 2006(8). doi:10.1158/1078-0432.CCR-05-2257
[10] CHEN J, WU H, HAN D. Using anti-VEGF McAb and magnetic nanoparticles as double-targeting vector for the radioimmunotherapy of liver cancer. 2006(2). doi:10.1016/j.canlet.2005.01.024
[11] MORGAN G J, KRISHNAN B, JENNER M. Advances in oral therapy for multiple myeloma. 2006(4). doi:10.1016/S1470-2045(6)70657-X
[12] NGUYEN Q D, RODRIGUES S, RODRIGUE C M. Inhibition of vascular endothelial growth factor (VEGF)-165 and semaphorin 3A-mediated cellular invasion and tumor growth by the VEGF signaling inhibitor ZD4190 in human colon cancer cells and xenografts. 2006(8). doi:10.1158/1535-7163.MCT-06-0044
[13] JONES-BOLIN S, ZHAO H, HUNTER K. The effects of the oral,pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice. 2006(7). doi:10.1158/1535-7163.MCT-05-0327
[14] ESCUDIER B, EISEN T, STADLER W M. Sorafenib in advanced clear-cell renal-cell carcinoma. 2007(2). doi:10.1056/NEJMoa060655
[15] ABOU-ALFA G K, SCHWARTZ L, RICCI S. Phase Ⅱ study of sorafenib in patients with advanced hepatocellular carcinoma. 2006(26). doi:10.1200/JCO.2005.01.3441
[16] VIDAL M, WELLS S, RYAN A. ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma. 2005(9). doi:10.1158/0008-5472.CAN-04-4561
[17] NATALE R, BODKIN D, GOVINDAN R. A comparison of the antitumor efficacy of ZD6474 and gefitinib in patients with NSCLC:results of a randomized double-blind phase Ⅱ study. 2005(z2). doi:10.1016/S0169-5002(5)80237-5
[18] HERBST R S, HEYMACH J V, O'REILLY M S. Vandetanib (ZD6474):an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. 2007(2). doi:10.1517/13543784.16.2.239
[19] DEMETRI G D, van OOSTEROM A T, GARRETT C R. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib:a randomised controlled trial. 2006(9544). doi:10.1016/S0140-6736(6)69446-4
[20] MOTZER R J, HUTSON T E, TOMCZAK P. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. 2007(2). doi:10.1056/NEJMoa065044
[21] RINI B I. SU11248 and AG013736:current data and future trials in renal cell carcinoma, 2005(3)
[22] SESSA C, VIGANO L, GRASSELLI G. Phase Ⅰ clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing. 2006(2). doi:10.1016/j.ejca.2005.09.033
[23] KULKE M H, BERGSLAND E K, RYAN D P. Phase Ⅱ study of recombinant human endostatin in patients with advanced neuroendocrine tumors. 2006(22). doi:10.1200/JCO.2006.05.6762
[24] 王金万, 孙燕, 刘永煜. 重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究. 中国肺癌杂志2005(4)
[25] KURUP A, LIN C W, MURRY D J. Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer:a phase Ⅱ study from Indiana University. 2006(1). doi:10.1093/annonc/mdj055
[26] TRAN H T, BLUMENSCHEIN G R, LU C. Clinical and pharmacokinetic study of TNP-470,an angiogenesis inhibitor,in combination with paclitaxel and carboplatin in patients with solid tumors. 2004(4). doi:10.1007/s00280-004-0816-z
[27] SPARANO J A, BERNARDO P, STEPHENSON P. Randomized phase Ⅲ trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy:Eastern Cooperative Oncology Group trial E2196. 2004(23). doi:10.1200/JCO.2004.08.054
[28] HEATH E I, BURTNESS B A, KLEINBERG L. Phase Ⅱ,parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (MMP) inhibitor prinomastat in patients with esophageal adenocarcinoma. 2006(2). doi:10.1007/s10637-006-5934-5
[29] LARA P N, STADLER W M, LONGMATE J. A randomized phase Ⅱ trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. 2006(5). doi:10.1158/1078-0432.CCR-05-2074
[30] LATREILLE J, BATIST G, LABERGE F. Phase Ⅰ/Ⅱ trial of the safety and efficacy of AE-941 (Ncovastat) in the treatment of non-small-cell lung cancer. 2003(4). doi:10.3816/CLC.2003.n.003
[31] DEZUBE B J, KROWN S E, LEE J Y. Randomized phase Ⅱ trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma:an AIDS Malignancy Consortium Study. 2006(9). doi:10.1200/JCO.2005.04.2614
[32] RAGUSE J D, GATH H J, BIER J. Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour. 2004(2). doi:10.1016/j.oraloncology.2003.08.003
[33] FRIESS H, LANGREHR J M, OETTLE H. A randomized multi-center phase Ⅱ trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. 2006. doi:10.1186/1471-2407-6-285 |
